Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment?
作者信息
Hogan Marie C, Masyuk Tatyana V
机构信息
Division of Nephrology & Hypertension, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Mayo Clinic Robert M. and Billie Kelley Pirnie Translational Polycystic Kidney Disease Center, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
出版信息
Clin J Am Soc Nephrol. 2023 Feb 1;18(2):154-156. doi: 10.2215/CJN.0000000000000055. Epub 2023 Jan 16.
Abstract
摘要
相似文献
1
Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment?
Clin J Am Soc Nephrol. 2023 Feb 1;18(2):154-156. doi: 10.2215/CJN.0000000000000055. Epub 2023 Jan 16.
2
Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon.
Adv Kidney Dis Health. 2023 May;30(3):245-260. doi: 10.1053/j.akdh.2023.01.003.
3
An update on tolvaptan for autosomal dominant polycystic kidney disease.
Drugs Today (Barc). 2018 Sep;54(9):519-533. doi: 10.1358/dot.2018.54.9.2776624.
4
Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease.
Pediatr Nephrol. 2017 May;32(5):893-896. doi: 10.1007/s00467-017-3584-9. Epub 2017 Feb 13.
5
Con: Tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers?
Nephrol Dial Transplant. 2019 Jan 1;34(1):35-37. doi: 10.1093/ndt/gfy298.
6
[ADPKD treatment: Tolvaptan and Octreotide].
G Ital Nefrol. 2019 Dec 9;36(6):2019-vol6.
7
Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
BMC Nephrol. 2018 Dec 19;19(1):368. doi: 10.1186/s12882-018-1176-y.
8
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17.
9
Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.
J Am Soc Nephrol. 2014 Jun;25(6):1140-7. doi: 10.1681/ASN.2013101037. Epub 2014 Feb 20.
10
Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
Pediatr Nephrol. 2018 Mar;33(3):395-408. doi: 10.1007/s00467-017-3672-x. Epub 2017 Apr 28.
引用本文的文献
1
Transforming advancing autosomal dominant polycystic kidney disease care: investigating new horizons in treatment and research.
Inflammopharmacology. 2025 Aug 14. doi: 10.1007/s10787-025-01894-9.
本文引用的文献
1
Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial.
Clin J Am Soc Nephrol. 2023 Feb 1;18(2):223-233. doi: 10.2215/CJN.0000000000000049.
2
Drug management of autosomal dominant polycystic kidney disease.
Aust Prescr. 2022 Oct;45(5):167-170. doi: 10.18773/austprescr.2022.052. Epub 2022 Oct 4.
3
Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis.
Int Urol Nephrol. 2023 Mar;55(3):631-640. doi: 10.1007/s11255-022-03353-8. Epub 2022 Sep 7.
4
Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.
Nephrol Dial Transplant. 2020 Aug 1;35(8):1306-1316. doi: 10.1093/ndt/gfz054.
5
The expression of somatostatin receptor 2 decreases during cyst growth in mice with polycystic kidney disease.
Exp Biol Med (Maywood). 2018 Sep;243(13):1092-1098. doi: 10.1177/1535370218803893. Epub 2018 Sep 27.
6
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161. doi: 10.2215/CJN.01520218. Epub 2018 Jul 19.
7
Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.
Mayo Clin Proc. 2015 Aug;90(8):1030-7. doi: 10.1016/j.mayocp.2015.05.011. Epub 2015 Jul 9.
8
Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.
J Am Soc Nephrol. 2015 Jan;26(1):39-47. doi: 10.1681/ASN.2013121312. Epub 2014 Jul 3.
9
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.
J Am Soc Nephrol. 2014 Jan;25(1):18-32. doi: 10.1681/ASN.2013040398. Epub 2013 Dec 12.
Zotero 插件